Table 1.
Study | Study duration (weeks) | Number of patients | Treatment comparison/dose (µg) | Mean age (years) |
Male (%) |
Baseline FEV1
% predicted |
COPD severity by lung function | Exacerbation risk by lung function | Exacerbation history in previous year | Exacerbation risk by previous AE |
---|---|---|---|---|---|---|---|---|---|---|
Bateman et al.13 | 26 | 474 | Indacaterol 110/glycopyrronium 50 | 64.0 | 76.4 | 55.7 | Moderate (63.8%) Severe (36.1%) | Low | 0 (73.7%) 1 (19.5%) ⩾2 (6.8%) | Low |
473 | Glycopyrronium 50 | 64.3 | 77.2 | 55.1 | ||||||
480 | Tiotropium 18 | 63.5 | 75.0 | 55.1 | ||||||
Wedzicha et al.14 | 64 | 729 | Indacaterol 110/glycopyrronium 50 | 63.1 | 76.0 | 37.0 | Severe (79.2%) Very severe (20.8%) |
High | 0 (1.5%) 1 (76.5%) ⩾2 (21.4%) | High |
740 | Glycopyrronium 50 | 63.1 | 73.0 | 37.3 | ||||||
737 | Tiotropium 18 | 63.6 | 75.0 | 37.4 | ||||||
Decramer et al.15 study 1 | 24 | 212 | Umeclidinium 62.5/vilanterol 25 | 63.0 | 70.0 | 48.0 | Moderate (48.0%) Severe (41.2%) Very severe (10.8%) |
High | 0 (51.2%) ⩾1 (48.8%) | Low |
208 | Tiotropium 18 | 62.6 | 67.0 | 47.8 | ||||||
Decramer et al.15 study 2 | 24 | 217 | Umeclidinium 62.5/vilanterol 25 | 65.0 | 65.0 | 47.7 | Moderate (43.9%) Severe (43.2%) Very severe (12.8%) |
High | 0 (66.5%) ⩾1 (33.5%) | Low |
222 | Umeclidinium 125 | 64.5 | 67.0 | 46.2 | ||||||
215 | Tiotropium 18 | 65.2 | 71.0 | 47.4 | ||||||
Maleki-Yazdi et al.16 | 24 | 454 | Umeclidinium 62.5/vilanterol 25 | 61.9 | 68.0 | 46.2 | Moderate (41.4%) Severe (45.6%) Very severe (12.9%) |
High | N/A | N/A |
451 | Tiotropium 18 | 62.7 | 67.0 | 46.5 | ||||||
Singh et al.17 | 24 | 385 | Aclidinium 400/formoterol 12 | 62.7 | 67.8 | 54.6 | Moderate (59.2%) Severe (40.8%) |
Low | N/A | N/A |
385 | Aclidinium 400 | 63.1 | 66.5 | 53.6 | ||||||
Buhl et al.12 | 52 | 1029 | Tiotropium 5/olodaterol 5 | 63.8 | 71.2 | 49.3 | Moderate (49.4%) Severe (38.6%) Very severe (12.0%) |
High | N/A | N/A |
1033 | Tiotropium 5 | 63.9 | 73.1 | 49.7 | ||||||
Hanania et al.18 | 52 | 1035 | Glycopyrrolate 18/formoterol 9.6 | 62.7 | 54.3 | 43.4 | Very severe (10.2%) | N/A | 0 (83.3%) 1 (9.5%) ⩾2 (7.2%) |
Low |
888 | Glycopyrrolate 18 | 62.8 | 55.9 | 42.6 | ||||||
450 | Tiotropium 18 | 62.9 | 59.6 | 42.7 | ||||||
D’Urzo et al.19 | 52 | 335 | Aclidinium 400/formoterol 12 | 64.2 | 50.1 | 53.2 | Moderate (56.3%) Severe (43.7%) |
Low | 0 (79.2%) ⩾1 (20.8%) | Low |
337 | Aclidinium 400 | 64.4 | 55.8 | 53.0 | ||||||
Calverley et al.8 | 52 | 3939 | Tiotropium 5/olodaterol 5 | 66.5 | 71.0 | 44.6 | N/A | N/A | 1 (55.7%) ⩾2 (44.3%) | High |
3941 | Tiotropium 5 | 66.3 | 72.0 | 44.5 |
AE, acute exacerbations; COPD, chronic obstructive pulmonary disease; FEV1, forced expiratory volume in the first second.